Skip to main content

European stem cell consortium for neural cell replacement, reprogramming and functional brain repair

Objective

Neurostemcellrepair aims at taking human stem cells through the final steps toward clinical application in cell replacement therapy for neurological disorders. PD will be taken as the prototypical disease because stem cell therapy is now close to clinical translation. Moreover, we will tackle next generation issues pertaining to stem cells at a basic level and develop new approaches and novel cell sources, validated at pre-clinical stages, for both PD and HD. The project teams represent a wide range of competences, including stem cell specialists, developmental neurobiologists, experts in neurodegeneration, scientists with links to the clinic and stem cell manufacturing/clinical validation. The research plan is constructed on exchange of tools, sharing of protocols and expertise and joint deliverables among the participants. We will address issues related to the control of progenitor proliferation and differentiation into authentic, functional and phenotypically stable dopaminergic or striatal neurons, and exploit new technology for cell reprogramming. We will develop strategies to obtain endurable donor cell engraftment in the host, including acquisition of specific neuronal identities and functional integration in the recipient brain. The therapeutic effect will be evaluated following transplantation in animal models of PD and HD. Cutting edge technologies will be guaranteed by the involvement of three SMEs, one industry and partners experienced in bioengineering, who will collectively provide a toolbox to deliver ontogenetic and reprogramming factors, small molecules and miRNA, immunoseparation strategies, in vivo monitoring of donor cell behaviour, scale up and GMP-compliant protocols. Ultimately, Neurostemcellrepair is expected to develop new cell sources based on cellular reprogramming, make significant advance towards stem cell therapy in HD, and close the gap between development and clinical implementation of stem cell replacement therapies for PD.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /medical and health sciences/clinical medicine/transplantation

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UNIVERSITA DEGLI STUDI DI MILANO
Address
Via Festa Del Perdono 7
20122 Milano
Italy
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 482 229,07

Participants (12)

MAX IV Laboratory, Lund University
Sweden
EU contribution
€ 564 594
Address
Paradisgatan 5C
22100 Lund
Activity type
Higher or Secondary Education Establishments
UNIVERSITATSKLINIKUM BONN
Germany
EU contribution
€ 485 000
Address
Venusberg-campus 1
53127 Bonn
Activity type
Higher or Secondary Education Establishments
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 523 200
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
CARDIFF UNIVERSITY
United Kingdom
EU contribution
€ 492 262
Address
Newport Road 30-36
CF24 ODE Cardiff
Activity type
Higher or Secondary Education Establishments
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 246 393
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI TORINO
Italy
EU contribution
€ 416 990
Address
Via Giuseppe Verdi 8
10124 Torino
Activity type
Higher or Secondary Education Establishments
THE UNIVERSITY OF EDINBURGH
United Kingdom
EU contribution
€ 438 000
Address
Old College, South Bridge
EH8 9YL Edinburgh
Activity type
Higher or Secondary Education Establishments
LAVISION BIOTEC GMBH

Participation ended

Germany
Address
Astastrasse 14
33617 Bielefeld
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INTEGRATED SYSTEMS ENGINEERING SRL
Italy
EU contribution
€ 180 000
Address
Via Volturno Cedri 80
20816 Brugherio
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Roslin Cells Ltd.
United Kingdom
EU contribution
€ 402 451,93
Address
C/o Roslin Foundation, Wallace Building, Roslin Biocentre
EH25 9PP Roslin, Midlothian
Activity type
Research Organisations
Administrative Contact
Kathryn Reilly (Mrs.)
Administrative Contact
Kathryn Reilly (Mrs.)
MILTENYI BIOTEC GMBH
Germany
EU contribution
€ 410 500
Address
Friedrich Ebert Strasse 68
51429 Bergish Gladbach
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
LIFE AND BRAIN GMBH
Germany
EU contribution
€ 358 380
Address
Venusberg-campus 1
53127 Bonn
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)